Enrolling Clinical Studies
URTICARIA CLINICAL TRIAL
We’re currently conducting a Clinical Trial for adults diagnosed with Urticaria, evaluating a new study-treatment. This study will assess the efficacy and safety of Barzolvolimab, a monoclonal antibody subcutaneous injection, in patients with Chronic Spontaneous Urticaria (chronic hives, red itchy bumps or welts on the skin) who remain symptomatic despite antihistamine treatment.
Requirements:
-
Men or Women 18 years of age or older.
-
Have a diagnosis of Chronic Spontaneous Urticaria 6 months or more prior screening.
-
Presence of active welts with swelling during the screening visit.
-
No history of other skin diseases with chronic itching e.g., psoriasis, atopic dermatitis.
-
Have not received a vaccine within 2 months prior screening: rubella, chicken pox, yellow fever
-
No history of chronic diseases e.g., hepatic, renal disease, diabetes, severe asthma, COPD, HIV.
-
No participants with active infection requiring treatment with antibiotics, antivirals, antifungals.
-
Not women who are pregnant of nursing prior study treatment.
-
Not using prohibited medications during screening, study treatment and follow-up.
Study Duration:
This study contains a total of 7 in-clinic visits over a period of 24 weeks.
Compensation:
Financial compensation up to $1,787 for time & transportation may be provided